The 40-gene expression profile (40-GEP) test identifies cutaneous squamous cell carcinoma (cSCC) patients at high risk of metastasis within lower-staged tumors to better guide treatment decisions
At the 2024 Fall Clinical Dermatology Conference for PAs and NPs, Ally-Khan Somani, MD, PhD, and co-authors presented a poster on their study utilizing the 40-gene expression profile (GEP) test for identifying cutaneous squamous cell carcinoma (cSCC) patients at high risk of metastasis.
By Ally-Khan Somani, MD, PhD | May 31, 2024
It is necessary to improve identification of tumors at risk of metastasis to guide clinical management. Though cSCC tumors may not have high-risk clinical features, there remains a possibility of metastasis. In a cohort of low-risk cSCC tumors (based on BHW and AJCC8 staging systems), the 40-GEP test was found to accurately identify tumors with a substantially higher risk of metastasis. The 40-GEP test stratified patients into Class 1, Class 2A, and Class 2B, with a greater number of Class 2A and 2B tumors resulting in metastasis. As such integrating this test into clinical practice can help stratify high-risk cSCC tumors and improve clinical decision-making. View the poster here.